CJC-1295 + Ipamorelin
CJC-1295 + Ipamorelin is a dual-peptide combination designed for research on growth hormone (GH) regulation and endocrine signaling. CJC-1295 (a GHRH analog, commonly the no-DAC/Mod GRF 1-29 form) stimulates GH release via the GHRH receptor, while Ipamorelin (a selective ghrelin receptor agonist) promotes GH secretion through the growth hormone secretagogue receptor (GHSR). The combination is widely used to study synergistic, pulsatile GH release with minimal impact on cortisol or prolactin pathways.
$154.00
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
Questions
CJC-1295 + IPA Common Questions
What’s pIC50?
pIC50 is the negative log of the IC50 value when converted to molar.That is, pIC50=-log(IC50).
What’s Kd?
Dissociation consent (Kd) reflects the affinity of a compound for its target. In some cases, it can be equivalent to Ki.
Product Introduction
Bioactivity
Description
CJC-1295 + Ipamorelin is a dual-peptide combination designed for research on growth hormone (GH) regulation and endocrine signaling. CJC-1295 (a GHRH analog, commonly the no-DAC/Mod GRF 1-29 form) stimulates GH release via the GHRH receptor, while Ipamorelin (a selective ghrelin receptor agonist) promotes GH secretion through the growth hormone secretagogue receptor (GHSR). The combination is widely used to study synergistic, pulsatile GH release with minimal impact on cortisol or prolactin pathways.
Targets & IC50
Targets:
Growth Hormone-Releasing Hormone Receptor (GHRHR)
Growth Hormone Secretagogue Receptor (GHSR)
cAMP Signaling Pathway
GH/IGF-1 Axis
IC50:
Not applicable
(agonist peptides; not characterized by inhibitory IC50 values)
In vitro
METHODS: Primary anterior pituitary cells and rat pituitary cell lines were treated with CJC-1295 (No DAC) (0–100 nM) in combination with Ipamorelin (0–100 nM) for 1–24 hours. Growth hormone secretion and intracellular signaling were assessed using ELISA and cAMP assays.
RESULTS: The combination of CJC-1295 and Ipamorelin produces a synergistic increase in growth hormone secretion compared to either peptide alone. CJC-1295 activates GHRHR-mediated cAMP signaling, while Ipamorelin stimulates GHSR, resulting in enhanced pulsatile GH release. The dual mechanism improves GH output efficiency without significant activation of cortisol or prolactin pathways. No significant cytotoxicity is observed within commonly used experimental concentrations. [1]
Synonyms
CJC-1295 / Ipamorelin blend
Chemical Properties
Molecular Weight
~3367.9 Da
Formula
Not applicable (multi-peptide combination)
Cas No.
Not applicable (individual peptides have separate CAS numbers)
Smiles
Not applicable (peptide mixture)
Relative Density.
no data available
Sequence
CJC-1295 (No DAC):
Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg
Ipamorelin:
Aib-His-D-2-Nal-D-Phe-Lys-NH₂
Sequence Short
CJC-1295: 29 aa. Ipamorelin: 5 aa
Storage & Solubility Information
Storage
Formula
Not applicable (multi-peptide combination)